Biomics Biotechnologies, founded in February 2006, is today Asia's leading RNA interference (RNAi) therapeutical technology company. It owns a portfolio of more than 40 patents and patent applications to protect its technologies and products.

"There exists a natural drug-making machine, RNAi, in all human cells, which was discovered by 2006 Nobel Prize winners in the US. I wished to turn RNAi mechanism into real therapeutics to cure many incurable diseases," says Dr York Zhu, who founded the company, explaining why he chose to focus on RNAi technology.

Dr York Zhu founded Biomics Biotechnologies after returning from the US to China. He invited venture capitalists to raise the funds for the company with the aim to become a leading player in RNAi in China. The company already has 100 employees and an industrial land of 100 acre in Nantong, Jiangsu province of China, where a 10,000 sq m pilot facility has been constructed.

The company has several products such as chemical synthesis of RNA, large-scale RNA synthesis of up to 100 gram and RNA modification and labeling. It also specializes in high throughput siRNA target screening (library base), RNA vector construction, dual luciferase reporting system, protein expression and RNAi-related services.

Its competence lies in its three centers: RNAi therapeutics R&D center, life science center and chemical synthesis center.